South Korean biopharmaceutical company GC Biopharma (KRX: 006280) announced on Wednesday that its US subsidiary, ABO Holdings, has received US Food and Drug Administration (FDA) approval for its plasma collection centre in Calexico, California.
The approval follows GC Biopharma's recent acquisition of ABO Holdings in January 2025, a strategic move aimed at supporting the long-term revenue potential of ALYGLO, its immune globulin intravenous product, which was recently launched in the US market.
With this authorisation, ABO Holdings now operates six plasma collection centres across California, Utah, and New Jersey. The company plans to intensify donor recruitment efforts in the second quarter to support expanded operations.
ABO Holdings is also constructing two additional plasma centres in Texas, with FDA approval targeted by 2027.
GC Biopharma anticipates that its source plasma business will enter into a phase of gradual growth in the latter half of 2025.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval